HYPR Stock Price, Hyperfine, Inc. Quote, Chart

Market Summary

USD0.91-0.08

Market Closed

-8.08%

HYPR Stock Price

View Fullscreen

HYPR RSI Chart

HYPR Valuation

Market Cap

69.3M

Price/Earnings (Trailing)

-1.57

Price/Sales (Trailing)

6.28

EV/EBITDA

0.15

Price/Free Cashflow

-1.63

HYPR Price/Sales (Trailing)

HYPR Profitability

EBT Margin

-401.00%

Return on Equity

-52.42%

Return on Assets

-46.96%

Free Cashflow Yield

-61.47%

HYPR Fundamentals

HYPR Revenue

Revenue (TTM)

11.0M

Rev. Growth (Yr)

88.62%

Rev. Growth (Qtr)

15.28%

HYPR Earnings

Earnings (TTM)

-44.2M

Earnings Growth (Yr)

18.19%

Earnings Growth (Qtr)

0.68%

Breaking Down HYPR Revenue

Last 7 days

-3%

Last 30 days

-17.8%

Last 90 days

-1.0%

Trailing 12 Months

-32.9%

How does HYPR drawdown profile look like?

HYPR Financial Health

Current Ratio

10.14

HYPR Investor Care

Shares Dilution (1Y)

1.51%

Diluted EPS (TTM)

-0.62

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	7.9M	9.8M	9.8M	11.0M
2022	2.7M	3.8M	5.8M	6.8M
2021	594.5K	895.0K	1.2M	1.5M
2020	0	0	0	294.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Hyperfine, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 16, 2024	teisseyre thomas	sold	-3,585	1.11	-3,230	chief operating officer
Nov 16, 2023	teisseyre thomas	sold	-3,345	1.26	-2,655	chief operating officer
Aug 16, 2023	teisseyre thomas	sold	-6,294	2.26	-2,785	chief operating officer
Aug 16, 2023	siddiqui khan	sold	-3,907	2.26	-1,729	cmo and chief strategy officer
May 16, 2023	siddiqui khan	sold	-2,168	1.25	-1,735	cmo and chief strategy officer
Feb 16, 2023	gupta alok	sold	-7,802	1.39	-5,613	chief financial officer
Feb 16, 2023	siddiqui khan	sold	-6,442	1.39	-4,635	cmo and chief strategy officer
Dec 16, 2022	hc sponsor llc	sold	-	-	-5,534,000	-
Dec 14, 2022	sainz maria	bought	4,750	0.95	5,000	president and ceo
Dec 09, 2022	sainz maria	acquired	10,561	0.85	12,425	president and ceo

Which funds bought or sold HYPR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 15, 2024	WEALTH ENHANCEMENT ADVISORY SERVICES, LLC	unchanged	-	-5,990	49,915	-%
Apr 15, 2024	Procyon Advisors, LLC	unchanged	-	-5,730	47,753	-%
Mar 11, 2024	VANGUARD GROUP INC	added	0.14	-2,944,290	3,556,820	-%
Feb 28, 2024	EP Wealth Advisors, LLC	unchanged	-	-32,294	38,892	-%
Feb 26, 2024	Virtu Financial LLC	new	-	84,000	84,000	0.01%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	23,875	23,875	-%
Feb 15, 2024	MERCER GLOBAL ADVISORS INC /ADV	unchanged	-	-18,000	22,000	-%
Feb 14, 2024	CITADEL ADVISORS LLC	new	-	163,035	163,035	-%
Feb 14, 2024	Avidity Partners Management LP	unchanged	-	-1,105,010	1,330,760	0.05%
Feb 14, 2024	Royal Bank of Canada	reduced	-89.69	-9,000	1,000	-%

Are Funds Buying or Selling HYPR?

Are funds buying HYPR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own HYPR

No. of Funds

Unveiling Hyperfine, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	5.62%	3,175,728	SC 13G
Feb 14, 2023	hc sponsor llc	0.0%	0	SC 13G/A
Dec 20, 2022	hc sponsor llc	12.0%	6,634,000	SC 13G/A
Dec 07, 2022	rothberg jonathan m	5.3%	2,976,688	SC 13D/A

Recent SEC filings of Hyperfine, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 16, 2024	PRE 14A	PRE 14A
Mar 28, 2024	4	Insider Trading
Mar 28, 2024	4	Insider Trading
Mar 28, 2024	4	Insider Trading
Mar 22, 2024	S-8	Employee Benefits Plan
Mar 22, 2024	424B5	Prospectus Filed
Mar 22, 2024	10-K	Annual Report
Mar 21, 2024	8-K	Current Report
Feb 16, 2024	4	Insider Trading
Feb 13, 2024	SC 13G	Major Ownership Report

Peers (Alternatives to Hyperfine, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	183.7B	40.1B	-5.40%	4.53%	32.1	4.58	-8.12%	-17.45%
BDX	67.1B	19.5B	-2.42%	-9.87%	53.41	3.44	4.02%	-22.04%
ALGN	22.6B	3.9B	-2.94%	-12.25%	50.69	5.84	3.42%	23.09%
BAX	20.1B	14.8B	-4.93%	-7.94%	7.56	1.35	2.12%	209.17%
MID-CAP
ATR	9.2B	3.5B	-1.69%	15.70%	32.17	2.62	4.97%	18.89%
HSIC	9.0B	12.3B	-4.49%	-14.03%	21.69	0.73	-2.44%	-22.68%
BIO	8.5B	2.7B	-12.27%	-39.23%	-13.34	3.18	-4.68%	82.43%
XRAY	6.3B	4.0B	-6.21%	-24.72%	-46.81	1.59	1.10%	85.84%
AXNX	3.4B	366.4M	-0.75%	15.36%	-564.66	9.35	33.86%	89.83%
PDCO	2.3B	6.6B	-5.91%	-4.69%	11.86	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-6.61%	-18.37%	-1.85	0.39	7.73%	-1066.14%
ANIK	382.1M	166.7M	0.59%	-11.05%	-4.62	2.29	6.67%	-456.34%
ANGO	253.5M	324.0M	21.04%	-28.41%	-1.32	0.78	-3.19%	-337.41%
APYX	48.2M	52.3M	-22.35%	-53.67%	-2.57	0.92	17.61%	19.28%
AEMD	3.8M	3.7M	-16.76%	269.23%	-0.31	1.01	5.77%	8.23%

Hyperfine, Inc. News

Latest updates

Hyperfine, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Revenue	15.3%	2,686,000	2,330,000	3,381,000	2,635,000	1,424,000	2,348,000	1,533,000	1,509,000	436,000	371,000	358,000	331,000	-
Gross Profit	-8.0%	1,034,000	1,124,000	1,444,000	1,155,000	300,000	688,000	-165,000	84,000	-453,000	-338,000	-99,000	-277,000	-
Operating Expenses	-1.7%	12,663,000	12,883,000	13,136,000	14,190,000	13,929,000	13,970,000	23,027,000	23,855,000	25,634,000	16,052,000	14,487,000	7,528,000	-
S&GA Expenses	0.0%	2,528,000	2,529,000	2,499,000	2,547,000	2,874,000	3,434,000	3,750,000	4,161,000	4,592,000	2,787,000	1,787,000	1,196,000	-
R&D Expenses	3.9%	5,962,000	5,739,000	5,331,000	5,461,000	5,219,000	7,338,000	7,265,000	8,334,000	8,893,000	6,438,000	6,037,000	4,474,000	-
EBITDA Margin	16.1%	-3.91	-4.66	-4.91	-7.62	-10.59	-14.61	-22.96	-29.90	-42.86	-19.35	-25.85	-38.92	-78.70
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	0.7%	-10,684,000	-10,757,000	-10,637,000	-12,160,000	-13,059,000	-13,171,000	-23,159,000	-23,775,000	-26,085,000	-16,392,000	-14,580,000	-7,794,000	-
EBT Margin	16.0%	-4.01	-4.77	-5.01	-7.75	-10.74	-14.79	-23.23	-30.23	-43.35	-19.60	-26.18	-39.41	-79.68
Net Income	0.7%	-10,684,000	-10,757,000	-10,637,000	-12,160,000	-13,059,000	-13,171,000	-23,159,000	-23,775,000	-26,085,000	-16,392,000	-14,580,000	-7,794,000	-
Net Income Margin	16.0%	-4.01	-4.77	-5.01	-7.75	-10.74	-14.79	-23.23	-30.23	-43.35	-19.60	-26.18	-39.41	-79.68
Free Cashflow	-13.5%	-10,196,000	-8,984,000	-9,881,000	-13,552,000	-15,503,000	-12,967,000	-16,857,000	-27,597,000	-19,110,000	-11,004,000	-12,123,000	-7,656,000	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Assets	-8.6%	94.00	103	113	122	134	148	162	179	202	81.00	208	208	72.00	31.00
Current Assets	-9.5%	89.00	98.00	108	117	129	144	157	174	197	76.00	1.00	1.00	68.00	28.00
Cash Equivalents	-12.0%	75.00	85.00	94.00	104	117	132	145	162	191	65.00	77.00	86.00	64.00	26.00
Inventory	-5.2%	7.00	7.00	6.00	6.00	5.00	4.00	5.00	5.00	4.00	3.00	-	-	2.00	-
Net PPE	-5.0%	3.00	3.00	3.00	3.00	3.00	3.00	3.00	4.00	4.00	3.00	-	-	2.00	0.00
Liabilities	5.4%	10.00	9.00	9.00	9.00	10.00	13.00	11.00	12.00	16.00	14.00	9.00	7.00	4.00	-
Current Liabilities	6.8%	9.00	8.00	8.00	8.00	9.00	12.00	10.00	11.00	16.00	14.00	1.00	0.00	4.00	2.00
Shareholder's Equity	-10.0%	84.00	94.00	103	113	124	135	151	167	186	-	5.00	5.00	0.00	-
Retained Earnings	-4.4%	-253	-243	-232	-221	-209	-196	-183	-160	-136	-110	-7.35	-5.92	-71.47	-48.04
Additional Paid-In Capital	0.4%	338	337	336	334	333	331	334	327	323	9.00	-	-	10.00	8.00
Shares Outstanding	0.2%	71.00	71.00	71.00	71.00	70.00	70.00	70.00	70.00	4.00	2.00	2.00	2.00	2.00	4.00
Float	-	-	-	116	-	-	-	121	-	-	-	204	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Cashflow From Operations	-14.0%	-9,938	-8,721	-9,659	-13,491	-15,345	-12,794	-16,911	-27,289	-18,135	-9,943	-11,618	-7,486	-	-	-
Share Based Compensation	7.9%	1,288	1,194	1,133	1,126	1,793	-2,354	7,102	4,111	3,770	1,375	1,489	267	-	-	-
Cashflow From Investing	1.9%	-258	-263	-222	-61.00	-158	-173	54.00	-308	-975	-1,061	-505	-170	-	-	-
Cashflow From Financing	-28.2%	28.00	39.00	58.00	49.00	5.00	-	-	-	141,328	1,264	2,965	31,210	-	-	-

HYPR Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Sales
Total sales	$ 11,032	$ 6,814
Cost of sales
Total cost of sales	6,275	5,907
Gross margin	4,757	907
Operating Expenses:
Research and development	22,493	28,156
General and administrative	20,276	32,406
Sales and marketing	10,103	14,219
Total operating expenses	52,872	74,781
Loss from operations	(48,115)	(73,874)
Interest income	3,842	761
Other income (expense), net	35	(51)
Loss before provision for income taxes	(44,238)	(73,164)
Provision for income taxes	0	0
Net loss and comprehensive loss	$ (44,238)	$ (73,164)
Earnings Per Share, Basic	$ (0.62)	$ (1.04)
Earnings Per Share, Diluted	$ (0.62)	$ (1.04)
Denominator for Basic EPS - weighted - average common stock	71,316,424	70,449,191
Denominator for Dilutive EPS - Weighted - average common stock	71,316,424	70,449,191
Device
Sales
Total sales	$ 8,746	$ 5,246
Cost of sales
Total cost of sales	4,463	4,231
Service
Sales
Total sales	2,286	1,568
Cost of sales
Total cost of sales	$ 1,812	$ 1,676

HYPR Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS:
Cash and cash equivalents	$ 75,183	$ 117,472
Restricted cash	621	771
Accounts receivable, less allowance of $321 and $180 in 2023 and 2022, respectively	3,189	2,103
Unbilled receivables	942	454
Inventory	6,582	4,622
Prepaid expenses and other current assets	2,391	3,194
Total current assets	88,908	128,664
Property and equipment, net	2,999	3,248
Other long term assets	2,292	2,139
Total assets	94,199	134,051
CURRENT LIABILITIES:
Accounts payable	1,214	678
Deferred grant funding	621	771
Deferred revenue	1,453	1,378
Accrued expenses and other current liabilities	5,419	5,976
Total current liabilities	8,768	8,803
Long term deferred revenue	968	1,526
Other noncurrent liabilities	64
Total liabilities	9,800	10,329
COMMITMENTS AND CONTINGENCIES (NOTE 13)
STOCKHOLDERS' EQUITY:
Additional paid-in capital	338,114	333,199
Accumulated deficit	(253,722)	(209,484)
Total stockholders' equity	84,399	123,722
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	94,199	134,051
Class A Common Stock
STOCKHOLDERS' EQUITY:
Common stock	5	5
Class B Common Stock
STOCKHOLDERS' EQUITY:
Common stock	2	2
Related Party
CURRENT ASSETS:
Due from related parties		$ 48
CURRENT LIABILITIES:
Due to related parties	$ 61

About Hyperfine, Inc.

Hyperfine, Inc., a medical device company, provides magnetic resonance imaging (MRI) products. Its products include Swoop Portable MR imaging system, which offers neuroimaging at the point of care. The company was incorporated in 2014 and is based in Guilford, Connecticut.

CEO	Ms. Maria Sainz
WEBSITE	https://hyperfine.io
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	136

Hyperfine, Inc. Frequently Asked Questions

What is the ticker symbol for Hyperfine, Inc.? What does HYPR stand for in stocks?

HYPR is the stock ticker symbol of Hyperfine, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Hyperfine, Inc. (HYPR)?

As of Tue Apr 16 2024, market cap of Hyperfine, Inc. is 69.32 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HYPR stock?

You can check HYPR's fair value in chart for subscribers.

What is the fair value of HYPR stock?

You can check HYPR's fair value in chart for subscribers. The fair value of Hyperfine, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Hyperfine, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HYPR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Hyperfine, Inc. a good stock to buy?

The fair value guage provides a quick view whether HYPR is over valued or under valued. Whether Hyperfine, Inc. is cheap or expensive depends on the assumptions which impact Hyperfine, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HYPR.

What is Hyperfine, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 16 2024, HYPR's PE ratio (Price to Earnings) is -1.57 and Price to Sales (PS) ratio is 6.28. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HYPR PE ratio will change depending on the future growth rate expectations of investors.